GlobeNewswire

Corvil Launches User-Centric Network Traffic Analysis For Accelerated Insider Threat Detection and Response

Dela

Solution automatically provides Security Analysts with a unified view of user identity, host and network activity in one system

DUBLIN, Ireland, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Corvil today announced the new release of its Security Analytics solution, which helps organizations identify malicious behavior from compromised user accounts that increase the risk of data theft and reputational damage.

With the coming introduction of regulations such as General Data Protection Regulation (GDPR), it is imperative that users and their data are protected by organizations. GDPR mandates notification of a data breach within seventy-two hours. Therefore, the ability to quickly detect abnormal user behavior, network access patterns and data exfiltration is essential.

Addressing these challenges, Corvil now provides unified, granular visibility and insight to activity across users, hosts, applications, and services.  By presenting a prioritized list of the most suspicious users in the environment as well as activity across associated devices of all types, security teams can rapidly see, understand and act on evasive threats and protect high-value assets.  

"In today's world, responding to insider threats depends on gaining comprehensive understanding of user activities across traditional IT domains - endpoints, networks, perimeters. Corvil's ability to provide comprehensive user activity insights into the security ecosystem represents a major step forward," said David Monahan, Managing Research Director, Security and Risk Management, Enterprise Management Associates, Inc.

The Corvil solution captures and analyzes L2-L7 network activity in real-time, contextually enriches with user identity and other data and automatically detects patterns of attack. Through streamlined workflows and intelligence sharing with the broader Security and Network Operations ecosystem (including SIEMs, Endpoint Detection and Response, Threat Intelligence, Next Generation Firewalls, and many big data systems), Security Teams can more effectively and efficiently combat threats in today's complex environments.  

With a single click, an analyst can quickly triage, forensically investigate and respond to incidents such as insider threats, evasive attack movements and ransomware attacks.  By providing linkage to the granular underlying communications, Security Teams can more quickly and with confidence, detect, identify the source, and determine the impact of breaches - live and retrospectively.

This solution is complemented by the machine learning-driven virtual security expert, Cara, released last year and deployed at some of the largest financial institutions in the world, to autonomously identify vulnerabilities and attacks in electronic financial transaction environments.  While Cara's daily cybersecurity intelligence report includes a cyber risk assessment score consumable by c-level executives, Corvil Security Analytics provides the additional granular, forensic record of user and host activity to help support compliance with emerging cybersecurity and data privacy regulations such as GDPR.

"Organizations today face unprecedented risk from cyber-attack and data loss," says Graham Ahearne, Director, Security Product Management. "As the automation and sophistication of attacks increases, all too often compromised user accounts, attacker footholds within the environment, and careless or malicious insiders are the elusive source.  Our new user-centric analytics provide security analysts with a unified view of all user activity on the host and on the network combined with automated risk-scoring, and actionable intelligence to accelerate detection, triage and response."

Security incidents expose organizations to reputational damage, legal and compliance exposure, and financial losses.  With more than 80 percent of breaches[1] stemming from inadvertent or malicious insiders, and with increasingly complex dynamic technology environments, organizations face new and growing threats every day. The faster an organization can identify and contain a data breach, the lower the costs.  However with a growing and diverse range of connected devices coupled with increasingly sophisticated and evasive attacks, it can take as long as five months[2] to detect a breach.  

Compounding matters, today's Security teams face shallow visibility and manual workflows often across fragmented systems while attempting to respond to a barrage of alerts.  While many technologies focus solely on a host-centric view of activity, attackers increasingly gain access through compromised user accounts, escalated privileges and covert communications that are undetectable without closer, more comprehensive analysis.

To learn more about Monitoring User Activity Across Network For Threat Detection and Response see details of our 2018 Corvil and Forrester Webinar.

Corvil's new Security Analytics release is generally available now.  For more information, or to contact a Corvil representative, please visit corvil.com.

About Corvil
Corvil is the industry leader for deriving Security, Operational, and Business intelligence from network data. As companies adopt faster and smarter machine technology, it becomes critical to tap into richer and more granular machine data sources to safeguard the transparency, performance and security of critical infrastructure and business applications. The Corvil streaming analytics platform captures, decodes, and learns from network data on the fly, transforming it into machine-time intelligence for network, IT, security and business teams to operate efficiently and securely in this new machine world. Corvil uses an open architecture to integrate the power of its network data analytics with the overall IT ecosystem providing increased automation and greater operational and business value outcomes for its users. The Corvil solution is trusted by leading financial institutions to safeguard their businesses across the globe involving 354 trillion messages with a daily transaction value in excess of $1 trillion.

Learn more about Corvil: Corvil.com | Twitter | LinkedIn 

Notes to the editor

[1] 81% of hacking-related breaches leveraged either stolen and/or weak passwords - 2017 Verizon DBIR. This means that 81% of attacks will come from hacker controlled machines inside the perimeter.
[2] Mean time to detect -
http://info.resilientsystems.com/hubfs/IBM_Resilient_Branded
_Content/White_Papers/2017_Global_CODB_Report_Final.pdf

Contact information: 
Press Office at Corvil
+353 1 859 1040
pressoffice@corvil.com 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Corvil via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum